The application of a new generation of ARPIs has improved the prognosis of patients on the one hand, but on the other hand, it has led to an increase in the clinical rate of AR-null prostate cancer, a refractory pathological type of PCa that is ineffective against commonly used androgen deprivation therapies. The gene discussed is AR; the disease is posterior cortical atrophy.